-
Loading metrics
Open Access
Peer-reviewed
Research Article
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo
-
Sheila Ranganath,
Affiliation Discovery Biology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Ashok Bhandari,
Affiliation Chemistry, Protagonist Therapeutics, Milpitas, CA, United States of America
⨯ -
Nicole Avitahl-Curtis,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Jaimee McMahon,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Derek Wachtel,
Affiliation DMPK, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Jenny Zhang,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Christopher Leitheiser,
Affiliation Pharmaceutical Development, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Sylvie G. Bernier,
Affiliation Discovery Biology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Guang Liu,
Affiliation Discovery Biology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Tran T. Tran,
Affiliation Protagonist Pty Ltd, Therapeutics Pty Ltd, Brisbane, Australia
⨯ -
Herodion Celino,
Affiliation Chemistry, Protagonist Therapeutics, Milpitas, CA, United States of America
⨯ -
Jenny Tobin,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Joon Jung,
Affiliation Chemistry, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Hong Zhao,
Affiliation Pharmaceutical Development, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Katie E. Glen,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Chris Graul,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Aliesha Griffin,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Wayne C. Schairer,
Affiliation Pharmaceutical Development, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Carolyn Higgins,
Affiliation DMPK, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Tammi L. Reza,
Affiliation Discovery Toxicology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Eva Mowe,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Sam Rivers,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Sonya Scott,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Alex Monreal,
Affiliation Discovery Biology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Courtney Shea,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Greg Bourne,
Affiliations Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia, Protagonist Pty Ltd, Therapeutics Pty Ltd, Brisbane, Australia
⨯ -
Casey Coons,
Affiliation Pharmaceutical Development, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Adaline Smith,
Affiliation Discovery Toxicology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Kim Tang,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Ramya A. Mandyam,
Affiliation Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia
⨯ -
Jaime Masferrer,
Affiliation Discovery Pharmacology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
David Liu,
Affiliation Biology, Protagonist Therapeutics, Milpitas, CA, United States of America
⨯ -
Dinesh V. Patel,
Affiliation Chemistry, Protagonist Therapeutics, Milpitas, CA, United States of America
⨯ -
Angelika Fretzen,
Affiliation Pharmaceutical Development, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Craig A. Murphy,
Affiliations Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia, Protagonist Pty Ltd, Therapeutics Pty Ltd, Brisbane, Australia
⨯ -
G. Todd Milne,
Affiliation Discovery Biology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ -
Mark L. Smythe,
Affiliations Institute for Molecular Biosciences, The University of Queensland, Brisbane, Australia, Protagonist Pty Ltd, Therapeutics Pty Ltd, Brisbane, Australia
⨯ - [ ... ],
-
Kenneth E. Carlson
* E-mail: kcarlson@ironwoodpharma.com
Affiliation Discovery Biology, Ironwood Pharmaceuticals, Cambridge, MA, United States of America
⨯ - [ view all ]
- [ view less ]
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo
- Sheila Ranganath,
- Ashok Bhandari,
- Nicole Avitahl-Curtis,
- Jaimee McMahon,
- Derek Wachtel,
- Jenny Zhang,
- Christopher Leitheiser,
- Sylvie G. Bernier,
- Guang Liu,
- Tran T. Tran
- Published: November 10, 2015
- https://doi.org/10.1371/journal.pone.0141330